Reconsidering resectable oncological conditions in pancreatic tail cancer : A multicenter retrospective study on prognostic factors in pancreatic tail cancer after resection (HOPS Pt-01)
Copyright © 2023 IAP and EPC. Published by Elsevier B.V. All rights reserved..
BACKGROUND: Pancreatic tail cancer (Pt-PC) is generally considered resectable when metastasis is absent, but doubts persist in clinical practice due to the variability in local tumor extent. We conducted a multicenter retrospective study to comprehensively identify prognostic factors associated with Pt-PC after resection.
METHODS: We enrolled 100 patients that underwent distal pancreatectomy. The optimal combination of factors influencing relapse-free survival (RFS) was determined using the maximum likelihood method (MLM) and corrected Akaike and Bayesian information criteria (AICc and BIC). Prognostic elements were then validated to predict oncological outcomes.
RESULTS: Therapeutic interventions included neoadjuvant treatment in 16 patients and concomitant visceral resection (CVR) in 37 patients; 89 patients achieved R0. Median RFS and OS after surgery were 23.1 and 37.1 months, respectively. AICc/BIC were minimized in the model with ASA-PS (≥2), CA19-9 (≥112 U/mL at baseline, non-normalized postoperatively), need for CVR, 6 pathological items (tumor diameter ≥19.5 mm, histology G1, invasion of the anterior pancreatic border, splenic vein invasion, splenic artery invasion, lymph node metastasis), and completed adjuvant treatment (cAT) for RFS. Regarding the predictive value of these 11 factors, area under the curve was 0.842 for 5-year RFS. Multivariate analysis of these 11 factors showed that predictors of RFS include CVR (hazard ratio, 2.13; 95 % confidence interval, 1.08-4.19; p = 0.028) and cAT (0.38, 0.19-0.76; p = 0.006).
CONCLUSIONS: The MLM identified certain Pt-PC cases warranting consideration beyond resectable during clinical management. Particular attention should be paid to conditions requiring CVR, even though immortal time bias remains unresolved with adjuvant treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al. - 24(2024), 1 vom: 15. Jan., Seite 109-118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kimura, Yasutoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant treatment |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 29.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pan.2023.12.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365946478 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365946478 | ||
| 003 | DE-627 | ||
| 005 | 20240129232026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pan.2023.12.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1274.xml |
| 035 | |a (DE-627)NLM365946478 | ||
| 035 | |a (NLM)38103948 | ||
| 035 | |a (PII)S1424-3903(23)01876-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kimura, Yasutoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reconsidering resectable oncological conditions in pancreatic tail cancer |b A multicenter retrospective study on prognostic factors in pancreatic tail cancer after resection (HOPS Pt-01) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 IAP and EPC. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Pancreatic tail cancer (Pt-PC) is generally considered resectable when metastasis is absent, but doubts persist in clinical practice due to the variability in local tumor extent. We conducted a multicenter retrospective study to comprehensively identify prognostic factors associated with Pt-PC after resection | ||
| 520 | |a METHODS: We enrolled 100 patients that underwent distal pancreatectomy. The optimal combination of factors influencing relapse-free survival (RFS) was determined using the maximum likelihood method (MLM) and corrected Akaike and Bayesian information criteria (AICc and BIC). Prognostic elements were then validated to predict oncological outcomes | ||
| 520 | |a RESULTS: Therapeutic interventions included neoadjuvant treatment in 16 patients and concomitant visceral resection (CVR) in 37 patients; 89 patients achieved R0. Median RFS and OS after surgery were 23.1 and 37.1 months, respectively. AICc/BIC were minimized in the model with ASA-PS (≥2), CA19-9 (≥112 U/mL at baseline, non-normalized postoperatively), need for CVR, 6 pathological items (tumor diameter ≥19.5 mm, histology G1, invasion of the anterior pancreatic border, splenic vein invasion, splenic artery invasion, lymph node metastasis), and completed adjuvant treatment (cAT) for RFS. Regarding the predictive value of these 11 factors, area under the curve was 0.842 for 5-year RFS. Multivariate analysis of these 11 factors showed that predictors of RFS include CVR (hazard ratio, 2.13; 95 % confidence interval, 1.08-4.19; p = 0.028) and cAT (0.38, 0.19-0.76; p = 0.006) | ||
| 520 | |a CONCLUSIONS: The MLM identified certain Pt-PC cases warranting consideration beyond resectable during clinical management. Particular attention should be paid to conditions requiring CVR, even though immortal time bias remains unresolved with adjuvant treatment | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adjuvant treatment | |
| 650 | 4 | |a Concomitant visceral resection | |
| 650 | 4 | |a Maximum likelihood method | |
| 650 | 4 | |a Pancreatic tail cancer | |
| 650 | 4 | |a Prognostic factor | |
| 700 | 1 | |a Nakamura, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Imamura, Masafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Nagayama, Minoru |e verfasserin |4 aut | |
| 700 | 1 | |a Murakami, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Tsuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Kimitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Kukita, Kazuharu |e verfasserin |4 aut | |
| 700 | 1 | |a Imai, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Masaki, Yoshiharu |e verfasserin |4 aut | |
| 700 | 1 | |a Motoya, Masayo |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwatani, Masaki |e verfasserin |4 aut | |
| 700 | 1 | |a Koyama, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohnishi, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Takemasa, Ichiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al. |d 2001 |g 24(2024), 1 vom: 15. Jan., Seite 109-118 |w (DE-627)NLM119887509 |x 1424-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:15 |g month:01 |g pages:109-118 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pan.2023.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 15 |c 01 |h 109-118 | ||